Health Canada accepts New Drug Submission for masitinib.

May 27, 2022 – AB Science announced that Health Canada has accepted its New Drug Submission (NDS) for masitinib. This step triggers a thorough regulatory review of the therapy under the Notice of Compliance with Conditions (NOC/c) pathway.

We will continue to post updates as we become aware of them. You can read more in AB Science’s press release. Specific questions about the treatment can be directed to the ALS Canada Research Team at research@als.ca.